人类免疫缺陷病毒损害非小细胞肺癌患者对肿瘤新抗原的免疫应答而不改变突变谱
该前瞻性研究比较了15例HIV感染者和12例免疫正常非小细胞肺癌患者的肿瘤免疫基因组特征,发现两组肿瘤突变负荷、分子谱及预测新抗原数量相似,但HIV感染者T细胞对新抗原的应答仅针对MHC II类限制性新抗原,且低CD4最低值与缺乏新抗原特异性应答相关。
要点
- HIV感染者与免疫正常者的肿瘤突变负荷、分子谱及预测新抗原数量相似。
- HIV感染者T细胞新抗原应答仅针对MHC II类限制性新抗原,而免疫正常者MHC I和II类均衡。
- 低CD4最低值与HIV感染者缺乏新抗原特异性应答相关。
核心结论
- HIV感染严重损害非小细胞肺癌患者局部和全身抗肿瘤免疫应答,尤其针对MHC I类限制性新抗原,尽管突变谱相似。
- 作者认为这些发现支持在该人群中使用基于MHC I类限制性新抗原的免疫治疗。
研究设计与样本
- 前瞻性比较15例HIV感染者和12例免疫正常非小细胞肺癌患者共27份肿瘤样本的免疫基因组特征。
- 采用肿瘤全外显子组和RNA测序及生物信息学流程分析肿瘤突变负荷、分子特征、肿瘤微环境和预测肿瘤新抗原。
- 通过离体干扰素γ酶联免疫斑点试验和细胞内细胞因子染色流式细胞术验证新抗原预测流程并研究抗肿瘤免疫应答。
主要发现
- 两组肿瘤突变负荷、分子谱、预测新抗原数量及其MHC I/II类预测限制性相似。
- T细胞对新抗原的应答在11例HIV感染者中可检出4例,在11例免疫正常者中可检出5例;HIV感染者仅针对MHC II类限制性新抗原,而免疫正常者MHC I和II类均衡。
- 细胞内细胞因子染色显示主要为单功能应答,主要由针对MHC II类限制性新抗原的产生肿瘤坏死因子-α的CD4 T细胞介导,以及针对MHC I类限制性新抗原的产生CD107、肿瘤坏死因子-α或干扰素γ的CD8 T细胞介导。
- 低CD4最低值与HIV感染者缺乏新抗原特异性应答相关。
- HIV感染者肿瘤微环境显示中性粒细胞比例较低和T细胞功能标志物降低。
临床怎么用
- 作者认为这些发现支持在该人群中使用基于MHC I类限制性新抗原的免疫治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NSCLC is frequent and associated with poor prognosis among people living with human immunodeficiency virus (PLWHIV); nevertheless, the contributing factors remain unknown. METHODS: We prospectively compared the immunogenomic characteristics of 27 NSCLC samples from 15 PLWHIV and 12 immunocompetent patients (ICs). Tumor whole-exome and RNA sequencing, along with a bioinformatics pipeline, allowed analysis of tumor mutational burden, molecular signatures, tumor microenvironment, and prediction of tumor neoepitopes. We conducted ex vivo interferon gamma (IFNγ) enzyme-linked ImmunoSpot assays and intracellular cytokine staining flow cytometry assays to functionally validate our bioinformatic pipeline for neoepitope prediction and to investigate the antitumor immune response. RESULTS: Tumor mutational burden, molecular profiles, number of predicted neoepitopes, and their major histocompatibility complex (MHC) class I/II predicted restriction were similar in both groups. Nevertheless, T-cell responses to neoepitopes, detectable in 4 out of 11 PLWHIV and 5 out of 11 IC, were exclusively directed against MHC class II-restricted neoepitopes in PLWHIV, whereas it was balanced between MHC class I and class II neoepitopes in IC. Intracellular cytokine staining revealed primarily monofunctional responses, mainly mediated by tumor necrosis factor-α-producing CD4 T-cells against MHC class II-restricted neoepitopes, and by CD8 T-cells producing CD107, tumor necrosis factor-α, or IFNγ against MHC class I-restricted neoepitopes. A low CD4 nadir was associated with the lack of neoepitope-specific responses in PLWHIV. Furthermore, PLWHIV tumor microenvironments displayed lower neutrophil proportions and decreased T-cell function markers. CONCLUSIONS: Our results indicate that despite similar mutational profiles, HIV infection severely impairs both local and systemic antitumor immune responses in patients with NSCLC, particularly to MHC class I-restricted neoepitopes. These findings support the use of MHC-class I-restricted neoepitope-based immunotherapy in this population.
引用
- Abbar B, Labreche K, Cadranel J, et al. Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLC. J Thorac Oncol. 2025. PMID: 39923848. doi:10.1016/j.jtho.2025.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。